Trident Mediquip Ltd.

Trident Lifeline Limited has successfully completed the acquisition of 51% stake in Trident Mediquip Limited (TML), as of February 4, 2025, at 09:32 AM. This acquisition involves the acquisition of a significant shareholding in TML, a company incorporated under CIN: U33309GJ2019PLC110421, and makes T-Med Biovation Private Limited (a wholly-owned subsidiary of TML) a stepdown subsidiary of Trident Lifeline Limited. The strategic acquisition will allow Trident Lifeline to tap into the fast-growing pharmaceuticals and medical & surgical equipment markets. T-Med Biovation, which was incorporated in July 2020, is focused on pharmaceutical products. Although the company had a modest turnover over the past years, with Rs. 32,007 in the 2023-24 financial year, the acquisition is seen as a long-term investment in the healthcare sector. The acquisition involves a related party transaction, as T-Med Biovation is a wholly-owned subsidiary of Trident Mediquip. The company’s promoters and board members also have interests in T-Med. Despite the related party status, the transaction is at arm’s length. There were no additional regulatory approvals required for this acquisition, which is now officially completed. For updates on this strategic acquisition and more business growth strategies, stay tuned to the latest corporate news.

This Microcap Pharma stock which deals in the business of pharma formulations under its own brands, loan license, and contract manufacturing model is in focus after the acquisition of 51% stake approval of Trident Mediquip. **Price Action** With a market capitalization of 310.48 Crores on Tuesday, the shares of **[Trident Lifeline Ltd](https://portal.tradebrains.in/stocks/543616)** fell by 1.82 percent marking a day’s low of Rs 270 compared to its previous closing price of Rs 410.70. The stock has delivered around 42 percent in the past year and has outperformed the Nifty Index. **What Happened** The stocks of Trident Lifeline rose after the company’s board to acquire 51 percent of Trident Mediquip. This acquisition would allow the company to aid in improving its presence. The time period for this acquisition is approximately one month. In FY24, the Trident Mediquip has Rs. 20.58 crore as turnover and it is in the business of pharmaceutical and chemical business. **About the Company** Trident Lifeline Limited was established in 2014. It is a pharmaceutical company focused on providing high-quality and affordable medications. Their business model includes manufacturing finished dosages under its own brands, utilizing a loan license model, and engaging in contract manufacturing. They operate primarily in emerging markets across Africa and Asia, with a strong global supply chain and a commitment to improving access to essential pharmaceuticals. Trident Lifeline aims to expand its product portfolio over the period. **Financials & Ratios** Its Revenue from operations increased by 57.42 percent year on year from Rs. 18.58 Crore in H1FY24 to Rs. 29.25 Crore in Q2FY25, accompanied by profits of Rs. 3.11 Crore to Rs. 4.41 Crore. In terms of Return ratios, it has reported a return on equity (ROE) of 12.06 percent and a return on capital employed (ROCE) of 14.99 percent. It has a net profit margin of 13.31 percent as of FY24. **Shareholding Pattern** As of September 2024, the shareholding pattern with the promoter’s stake holding a share of 62.99 percent in Trident Lifeline, Foreign Institutional investors (FII) holding around 6.09 percent, and public holdings standing at 30.92 percent.